OBJECTIVE: Early HIV infection is characterized by a dramatic depletion of CD4 T cells in the gastrointestinal tract and translocation of bacterial products from the gut into the blood. In this study, we evaluated if gut bacterial profiles were associated with immune status before and after starting antiretroviral therapy (ART). DESIGN: We evaluated the gut microbiota of men recently infected with HIV (n = 13) who were participating in a randomized, double-blind controlled trial of combination ART and maraviroc versus placebo and who were followed for 48 weeks. METHODS: To evaluate the gut microbiota of participants, we pyrosequenced the bacterial populations from anal swabs collected before and longitudinally after the initiation of ART. Associations of the gut flora with clinical variables (lymphocyte profiles and viral loads), activation and proliferation markers in peripheral blood mononuclear cells and gut biopsies (measured by flow cytometry) and markers of microbial translocation (lipopolysaccharide and soluble CD14) were performed by regression analyses using R statistical software. RESULTS: Using pyrosequencing, we identified that higher proportions of Lactobacillales in the distal gut of recently HIV-infected individuals were associated with lower markers of microbial translocation, higher CD4% and lower viral loads before ART was started. Similarly, during ART, higher proportions of gut Lactobacillales were associated with higher CD4%, less microbial translocation, less systemic immune activation, less gut T lymphocyte proliferation, and higher CD4% in the gut. CONCLUSION: Shaping the gut microbiome, especially proportions of Lactobacillales, could help to preserve immune function during HIV infection.
RCT Entities:
OBJECTIVE: Early HIV infection is characterized by a dramatic depletion of CD4 T cells in the gastrointestinal tract and translocation of bacterial products from the gut into the blood. In this study, we evaluated if gut bacterial profiles were associated with immune status before and after starting antiretroviral therapy (ART). DESIGN: We evaluated the gut microbiota of men recently infected with HIV (n = 13) who were participating in a randomized, double-blind controlled trial of combination ART and maraviroc versus placebo and who were followed for 48 weeks. METHODS: To evaluate the gut microbiota of participants, we pyrosequenced the bacterial populations from anal swabs collected before and longitudinally after the initiation of ART. Associations of the gut flora with clinical variables (lymphocyte profiles and viral loads), activation and proliferation markers in peripheral blood mononuclear cells and gut biopsies (measured by flow cytometry) and markers of microbial translocation (lipopolysaccharide and soluble CD14) were performed by regression analyses using R statistical software. RESULTS: Using pyrosequencing, we identified that higher proportions of Lactobacillales in the distal gut of recently HIV-infected individuals were associated with lower markers of microbial translocation, higher CD4% and lower viral loads before ART was started. Similarly, during ART, higher proportions of gut Lactobacillales were associated with higher CD4%, less microbial translocation, less systemic immune activation, less gut T lymphocyte proliferation, and higher CD4% in the gut. CONCLUSION: Shaping the gut microbiome, especially proportions of Lactobacillales, could help to preserve immune function during HIV infection.
Authors: Claudia F Althaus; Sara Gianella; Philip Rieder; Viktor von Wyl; Roger D Kouyos; Barbara Niederöst; Adrian Schmid; Karin J Metzner; Beda Joos; Huldrych F Günthard; Marek Fischer Journal: J Virol Methods Date: 2010-01-29 Impact factor: 2.014
Authors: Sara Gianella; Christy M Anderson; Milenka V Vargas; Douglas D Richman; Susan J Little; Sheldon R Morris; Davey M Smith Journal: J Infect Dis Date: 2012-12-28 Impact factor: 5.226
Authors: Maria G Dominguez-Bello; Elizabeth K Costello; Monica Contreras; Magda Magris; Glida Hidalgo; Noah Fierer; Rob Knight Journal: Proc Natl Acad Sci U S A Date: 2010-06-21 Impact factor: 11.205
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Collin L Ellis; Zhong-Min Ma; Surinder K Mann; Chin-Shang Li; Jian Wu; Thomas H Knight; Tammy Yotter; Timothy L Hayes; Archana H Maniar; Paolo V Troia-Cancio; Heather A Overman; Natalie J Torok; Anthony Albanese; John C Rutledge; Christopher J Miller; Richard B Pollard; David M Asmuth Journal: J Acquir Immune Defic Syndr Date: 2011-08-15 Impact factor: 3.731
Authors: Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman Journal: J Virol Date: 2008-03-19 Impact factor: 5.103
Authors: Susan A Tuddenham; Wei Li A Koay; Ni Zhao; James R White; Khalil G Ghanem; Cynthia L Sears Journal: Clin Infect Dis Date: 2020-02-03 Impact factor: 9.079
Authors: Stephanie M Dillon; Jon Kibbie; Eric J Lee; Kejun Guo; Mario L Santiago; Gregory L Austin; Sara Gianella; Alan L Landay; Andrew M Donovan; Daniel N Frank; Martin D McCARTER; Cara C Wilson Journal: AIDS Date: 2017-02-20 Impact factor: 4.177
Authors: S Serrano-Villar; J F Vázquez-Castellanos; A Vallejo; A Latorre; T Sainz; S Ferrando-Martínez; D Rojo; J Martínez-Botas; J Del Romero; N Madrid; M Leal; J I Mosele; M J Motilva; C Barbas; M Ferrer; A Moya; S Moreno; M J Gosalbes; V Estrada Journal: Mucosal Immunol Date: 2016-12-21 Impact factor: 7.313
Authors: J F Vázquez-Castellanos; S Serrano-Villar; A Latorre; A Artacho; M L Ferrús; N Madrid; A Vallejo; T Sainz; J Martínez-Botas; S Ferrando-Martínez; M Vera; F Dronda; M Leal; J Del Romero; S Moreno; V Estrada; M J Gosalbes; A Moya Journal: Mucosal Immunol Date: 2014-11-19 Impact factor: 7.313
Authors: Liying Yang; Michael A Poles; Gene S Fisch; Yingfei Ma; Carlos Nossa; Joan A Phelan; Zhiheng Pei Journal: AIDS Date: 2016-01-02 Impact factor: 4.177